Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Adult
Alemtuzumab
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Crotonates
/ therapeutic use
Dimethyl Fumarate
/ therapeutic use
Female
Fingolimod Hydrochloride
/ therapeutic use
Glatiramer Acetate
/ therapeutic use
Humans
Hydroxybutyrates
Interferon-beta
/ therapeutic use
Multiple Sclerosis
/ complications
Natalizumab
/ therapeutic use
Nitriles
Pregnancy
Pregnancy Complications
/ epidemiology
Pregnancy Outcome
/ epidemiology
Prospective Studies
Rituximab
/ therapeutic use
Toluidines
/ therapeutic use
breastfeeding
disease modifying therapy
multiple sclerosis
pregnancy
relapses
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
21 Jan 2020
21 Jan 2020
Historique:
received:
23
11
2019
revised:
17
12
2019
accepted:
16
01
2020
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Pregnancy rates are rapidly increasing among women of reproductive age diagnosed with multiple sclerosis (MS). Through pre-conception, pregnancy and post-partum periods, there is a need for disease control management, to decrease chances of MS relapses while avoiding potential risks to the mother and the fetus. However, pregnancy is not always compatible with the available highly effective MS treatments. This narrative review provides the aspects of pregnancy's outcomes and the impact on disease activity, choices of anesthesia and the management of relapses during the pregnancy and breastfeeding period. Available disease modifying treatment is discussed in the article with new data supporting the strategy of continuing natalizumab after conception, as it is related to a decreased risk of MS relapses during the pregnancy and postpartum period.
Identifiants
pubmed: 31973138
pii: medicina56020049
doi: 10.3390/medicina56020049
pmc: PMC7074401
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Crotonates
0
Hydroxybutyrates
0
Natalizumab
0
Nitriles
0
Toluidines
0
teriflunomide
1C058IKG3B
Alemtuzumab
3A189DH42V
Rituximab
4F4X42SYQ6
Glatiramer Acetate
5M691HL4BO
Interferon-beta
77238-31-4
ocrelizumab
A10SJL62JY
Dimethyl Fumarate
FO2303MNI2
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Am J Obstet Gynecol. 2007 Dec;197(6):585.e1-7; discussion 683-4, e1-7
pubmed: 18060943
Mult Scler. 2010 Aug;16(8):950-5
pubmed: 20542921
Neurol Ther. 2015 Dec;4(2):93-104
pubmed: 26662361
Autoimmun Rev. 2019 Oct;18(10):102360
pubmed: 31401345
Neurology. 2020 May 5;94(18):e1939-e1949
pubmed: 32284359
J Hum Lact. 2015 May;31(2):237-9
pubmed: 25691380
Neurology. 2014 Feb 25;82(8):674-80
pubmed: 24463630
Arthritis Rheum. 2012 Jul;64(7):2085-94
pubmed: 22307734
Int J MS Care. 2011 Summer;13(2):91-3
pubmed: 24453710
Mult Scler. 2015 Jan;21(1):41-7
pubmed: 25145691
JAMA Neurol. 2015 Oct;72(10):1132-8
pubmed: 26322399
Blood. 2011 Feb 3;117(5):1499-506
pubmed: 21098742
J Magn Reson Imaging. 2011 Oct;34(4):750-7
pubmed: 21928308
Neurol Sci. 2017 Oct;38(10):1849-1858
pubmed: 28770366
Autoimmun Rev. 2011 Jun;10(8):495-502
pubmed: 21354338
Lung Cancer. 2013 Dec;82(3):499-505
pubmed: 24091171
Eur J Neurol. 2015 Oct;22 Suppl 2:34-9
pubmed: 26374512
JAMA Neurol. 2014 Jul 1;71(7):891-5
pubmed: 24821217
BMC Neurol. 2012 Dec 31;12:165
pubmed: 23276328
Front Immunol. 2017 Apr 18;8:425
pubmed: 28458668
Brain Behav. 2018 Sep;8(9):e01082
pubmed: 30047260
Neurologia (Engl Ed). 2019 May;34(4):259-269
pubmed: 27546613
Neurotherapeutics. 2017 Oct;14(4):974-984
pubmed: 28766273
BMC Neurol. 2016 Aug 24;16(1):150
pubmed: 27552976
Continuum (Minneap Minn). 2016 Aug;22(3):837-50
pubmed: 27261685
Mult Scler Int. 2016;2016:1034912
pubmed: 28078140
Mult Scler. 2018 Feb;24(2):96-120
pubmed: 29353550
Neurol Ther. 2018 Jun;7(1):59-85
pubmed: 29243029
Neurology. 2018 Oct 23;91(17):e1559-e1569
pubmed: 30266889
Ann Neurol. 2011 Jul;70(1):41-50
pubmed: 21710652
Mult Scler Relat Disord. 2019 Jul;32:54-63
pubmed: 31030020
Mult Scler. 2013 Mar;19(3):351-8
pubmed: 22760102
Am J Epidemiol. 2019 Jan 1;188(1):57-66
pubmed: 30165561
Ther Adv Neurol Disord. 2016 May;9(3):198-210
pubmed: 27134675
Vasc Cell. 2014 Nov 28;6(1):23
pubmed: 25473485
Pract Neurol. 2019 Apr;19(2):106-114
pubmed: 30612100
N Engl J Med. 1998 Jul 30;339(5):285-91
pubmed: 9682040
Clin Transl Oncol. 2014 Feb;16(2):122-7
pubmed: 24002946
Neurol Clin. 2019 Feb;37(1):17-30
pubmed: 30470273
JAMA Neurol. 2016 May 1;73(5):515-9
pubmed: 26953778
Crit Rev Oncol Hematol. 2016 Feb;98:29-34
pubmed: 26481954
Rev Neurol (Paris). 2014 Apr;170(4):247-65
pubmed: 24684929